StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Reblozyl (luspatercept by Quarter

Reblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M) ($M)

QuarterlyAnnual

Merck Reblozyl (luspatercept: $122M in Q2 2026, up 14.0% from a year earlier.

Latest, Q2 2026
122
Period ended Jun 30, 2026
Change on a year earlier
+14.0%
107 in Q2 2025
History
22 quarters
Since Q1 2021
Sources
8
Documents cited below

Where the Q2 2026 figure comes from

“|| Alliance Revenue – Reblozyl (3) | 122 | 107 | 15 | 98 | 88 | 11 | 25 | 19 | 31”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedReblozyl (luspatercept — BMS hematology/oncology royalty revenue) — Worldwide sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026122+14.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026148+24.4%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 2025164+49.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025136+36.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025107+18.9%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025119+67.6%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024110+57.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024100+92.3%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q2 2024Jun 30, 202490+91.5%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q1 2024Mar 31, 202471+65.1%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 202370+70.7%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 202352+33.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q2 2023Jun 30, 202347+42.4%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q1 2023Mar 31, 202343-17.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 202241+141.2%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 202239–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗

Breakdown

What makes up reblozyl (luspatercept

Cite this data

StockData. (2026). Merck Reblozyl (luspatercept ($M), quarterly Q1 2021–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-reblozyl

See every metric in the Merck KPI table. Data updated Oct 26, 2026.